JP2007516213A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007516213A5 JP2007516213A5 JP2006523297A JP2006523297A JP2007516213A5 JP 2007516213 A5 JP2007516213 A5 JP 2007516213A5 JP 2006523297 A JP2006523297 A JP 2006523297A JP 2006523297 A JP2006523297 A JP 2006523297A JP 2007516213 A5 JP2007516213 A5 JP 2007516213A5
- Authority
- JP
- Japan
- Prior art keywords
- heterozygote
- monoclonal antibody
- binding arm
- binding
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000005614 monoclonal antibodies Human genes 0.000 claims 16
- 108010045030 monoclonal antibodies Proteins 0.000 claims 16
- -1 CD3 Proteins 0.000 claims 11
- 230000035693 Fab Effects 0.000 claims 7
- 102000004965 antibodies Human genes 0.000 claims 7
- 108090001123 antibodies Proteins 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 3
- 206010059512 Apoptosis Diseases 0.000 claims 2
- 102100013858 BSG Human genes 0.000 claims 2
- 108060001249 CD24 Proteins 0.000 claims 2
- 102100000197 CD24 Human genes 0.000 claims 2
- 102100016493 CD33 Human genes 0.000 claims 2
- 101700017647 CD33 Proteins 0.000 claims 2
- 102100016530 CD37 Human genes 0.000 claims 2
- 101700044364 CD37 Proteins 0.000 claims 2
- 102100003279 CD38 Human genes 0.000 claims 2
- 101700044948 CD38 Proteins 0.000 claims 2
- 101710040446 CD40 Proteins 0.000 claims 2
- 102100013137 CD40 Human genes 0.000 claims 2
- 102100013076 CD48 Human genes 0.000 claims 2
- 101700012453 CD48 Proteins 0.000 claims 2
- 102100019283 CD52 Human genes 0.000 claims 2
- 108010065524 CD52 Antigen Proteins 0.000 claims 2
- 102100013391 CD55 Human genes 0.000 claims 2
- 101710006195 CD55 Proteins 0.000 claims 2
- 101700073334 CD59 Proteins 0.000 claims 2
- 102100003281 CD59 Human genes 0.000 claims 2
- 102100005830 CD70 Human genes 0.000 claims 2
- 101700017377 CD70 Proteins 0.000 claims 2
- 101710007476 CD74 Proteins 0.000 claims 2
- 102100004099 CD74 Human genes 0.000 claims 2
- 102100019451 CD80 Human genes 0.000 claims 2
- 101700080477 CD80 Proteins 0.000 claims 2
- 102100008191 CD8A Human genes 0.000 claims 2
- 101700054655 CD8A Proteins 0.000 claims 2
- 102100011842 CEACAM5 Human genes 0.000 claims 2
- 101700020447 CR2 Proteins 0.000 claims 2
- 102100009368 CR2 Human genes 0.000 claims 2
- 102000008646 Carbonic Anhydrase IX Human genes 0.000 claims 2
- 108010088013 Carbonic Anhydrase IX Proteins 0.000 claims 2
- 102100016662 ERBB2 Human genes 0.000 claims 2
- 101700025368 ERBB2 Proteins 0.000 claims 2
- 102000027776 ERBB3 Human genes 0.000 claims 2
- 101700041204 ERBB3 Proteins 0.000 claims 2
- 102100009851 ERBB4 Human genes 0.000 claims 2
- 101700023619 ERBB4 Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 101700079540 FAS Proteins 0.000 claims 2
- 101700053597 FCER2 Proteins 0.000 claims 2
- 102100014608 FCER2 Human genes 0.000 claims 2
- 101700010580 FLO11 Proteins 0.000 claims 2
- 102100008658 FN1 Human genes 0.000 claims 2
- 102100008453 FOLH1 Human genes 0.000 claims 2
- 101700036477 FOLH1 Proteins 0.000 claims 2
- 108010067306 Fibronectins Proteins 0.000 claims 2
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 2
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 2
- 102100006815 IL2RA Human genes 0.000 claims 2
- 101700082799 IL2RA Proteins 0.000 claims 2
- 101700015336 ISG20 Proteins 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 102000004889 Interleukin-6 Human genes 0.000 claims 2
- 101700058542 KLK3 Proteins 0.000 claims 2
- 108090000028 MMP12 Proteins 0.000 claims 2
- 102100006037 MUC1 Human genes 0.000 claims 2
- 101700052761 MUC1 Proteins 0.000 claims 2
- 102100006044 MUC16 Human genes 0.000 claims 2
- 101700010570 MUC17 Proteins 0.000 claims 2
- 102100013951 MUC2 Human genes 0.000 claims 2
- 101700036633 MUC2 Proteins 0.000 claims 2
- 102100013952 MUC3A Human genes 0.000 claims 2
- 101700075415 MUC3A Proteins 0.000 claims 2
- 102100013929 MUC4 Human genes 0.000 claims 2
- 101700032853 MUC4 Proteins 0.000 claims 2
- 102100008795 NGFR Human genes 0.000 claims 2
- 102100002997 NPEPPS Human genes 0.000 claims 2
- 101710027788 NPEPPS Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102000003729 Neprilysin Human genes 0.000 claims 2
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 claims 2
- 229920000272 Oligonucleotide Polymers 0.000 claims 2
- 102100004939 PDGFRB Human genes 0.000 claims 2
- 101710018346 PDGFRB Proteins 0.000 claims 2
- 102100012897 PGF Human genes 0.000 claims 2
- 108060006216 PIGF Proteins 0.000 claims 2
- 101710025567 PSAT1 Proteins 0.000 claims 2
- 101700008337 PSMA Proteins 0.000 claims 2
- 101710037934 QRSL1 Proteins 0.000 claims 2
- 101700044827 RNMT Proteins 0.000 claims 2
- 102100010587 SDC1 Human genes 0.000 claims 2
- 102100003095 TNFRSF1A Human genes 0.000 claims 2
- 101710038526 TNFRSF1A Proteins 0.000 claims 2
- 102100003105 TNFRSF1B Human genes 0.000 claims 2
- 101710038524 TNFRSF1B Proteins 0.000 claims 2
- 101710040533 TNFRSF8 Proteins 0.000 claims 2
- 102100009538 TNFRSF8 Human genes 0.000 claims 2
- 102000007000 Tenascin Human genes 0.000 claims 2
- 108010008125 Tenascin Proteins 0.000 claims 2
- 102100015249 VEGFA Human genes 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 101710019504 XAB2 Proteins 0.000 claims 2
- 230000003042 antagnostic Effects 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 230000001640 apoptogenic Effects 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 239000002738 chelating agent Substances 0.000 claims 2
- 230000037320 fibronectin Effects 0.000 claims 2
- 101700068417 fol1 Proteins 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 2
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 claims 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 claims 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 claims 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 claims 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 claims 1
- 229940114721 Enzymes FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM Drugs 0.000 claims 1
- 229940093738 Enzymes for ALIMENTARY TRACT AND METABOLISM Drugs 0.000 claims 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 claims 1
- 229940088597 Hormone Drugs 0.000 claims 1
- 241000406221 Hypostomus robinii Species 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 229960004961 Mechlorethamine Drugs 0.000 claims 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N Monomethylhydrazine Chemical class CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 claims 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N Nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 claims 1
- 206010025310 Other lymphomas Diseases 0.000 claims 1
- JVHROZDXPAUZFK-UHFFFAOYSA-N TETA Chemical compound OC(=O)CN1CCCN(CC(O)=O)CCN(CC(O)=O)CCCN(CC(O)=O)CC1 JVHROZDXPAUZFK-UHFFFAOYSA-N 0.000 claims 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims 1
- 229960003433 Thalidomide Drugs 0.000 claims 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N Thalidomide Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 claims 1
- 231100000765 Toxin Toxicity 0.000 claims 1
- AYNNSCRYTDRFCP-UHFFFAOYSA-N Triazene Chemical compound NN=N AYNNSCRYTDRFCP-UHFFFAOYSA-N 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- 230000001780 adrenocortical Effects 0.000 claims 1
- 229930013930 alkaloids Natural products 0.000 claims 1
- 150000008052 alkyl sulfonates Chemical class 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007172 antigens Proteins 0.000 claims 1
- 102000038129 antigens Human genes 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 229940019336 antithrombotic Enzymes Drugs 0.000 claims 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims 1
- 102000024070 binding proteins Human genes 0.000 claims 1
- 108091007650 binding proteins Proteins 0.000 claims 1
- 230000003115 biocidal Effects 0.000 claims 1
- 150000001639 boron compounds Chemical class 0.000 claims 1
- 235000013877 carbamide Nutrition 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 108091006028 chimera Proteins 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 230000001809 detectable Effects 0.000 claims 1
- 231100000673 dose–response relationship Toxicity 0.000 claims 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical class C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037240 fusion proteins Human genes 0.000 claims 1
- 229940020899 hematological Enzymes Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229940121354 immunomodulators Drugs 0.000 claims 1
- 229940079866 intestinal antibiotics Drugs 0.000 claims 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 claims 1
- 229940083249 peripheral vasodilators Enzymes Drugs 0.000 claims 1
- 239000000906 photoactive agent Substances 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 claims 1
- 150000003230 pyrimidines Chemical class 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 108020003112 toxins Proteins 0.000 claims 1
- 102000003995 transcription factors Human genes 0.000 claims 1
- 108090000464 transcription factors Proteins 0.000 claims 1
- 150000003672 ureas Chemical class 0.000 claims 1
Claims (26)
- 一つの第一の結合アームと一つの第二の結合アームとを少なくとも含んでなるヘテロ接合体であって、
前記第一の結合アームが、前記第二の結合アームと異なる結合特異性を有し、
前記ヘテロ接合体と罹患細胞が接触したときに、前記ヘテロ接合体が前記細胞の増殖を阻害しかつアポトーシスを誘発することを特徴とする、ヘテロ接合体。 - 前記第一および第二の結合アームが、互いに接合されていない状態では、アポトーシス活性を有しないものである、請求項1に記載のヘテロ接合体。
- 前記結合アームの少なくとも一つが、抗体またはそのフラグメントである、請求項1に記載のヘテロ接合体。
- 前記ヘテロ接合体が、前記第一および前記第二の結合アームを含んでなる融合タンパク質を含んでなるものである、請求項1に記載のヘテロ接合体。
- 前記第一および前記第二の結合アームが、化学結合を介して接合している、請求項1に記載のヘテロ接合体。
- 前記ヘテロ接合体が互いに架橋することなく用量依存的にアポトーシスを誘発する、請求項1に記載のヘテロ接合体。
- 前記第一の結合アームが、CD2、CD3、CD8、CD10、CD21、CD23、CD24、CD25、CD30、CD33、CD37、CD38、CD40、CD48、CD52、CD55、CD59、CD70、CD74、CD80、CD86、CD138、CD147、HLA-DR、CEA、CSAp、CA-125、TAG-72、EFGR、HER2、HER3、HER4、IGF-1R、c-Met、PDGFR、MUC1、MUC2、MUC3、MUC4、TNFR1、TNFR2、NGFR、Fas (CD95)、DR3、DR4、DR5、DR6、VEGF、PIGF、ED-Bフィブロネクチン、テネイシン、PSMA、PSA、カルボニックアンヒドラーゼIXおよびIL-6 をターゲットとする結合アームからなる群から選択されるものである、請求項1に記載のヘテロ接合体。
- 前記第一の結合アームが、リンパ腫または固形腫瘍と関連したヒト腫瘍ターゲットに特異的に結合する、請求項1に記載のヘテロ接合体。
- 前記第二の結合アームが、CD2、CD3、CD8、CD10、CD21、CD23、CD24、CD25、CD30、CD33、CD37、CD38、CD40、CD45Ro、CD48、CD52、CD55、CD59、CD70、CD74、CD80、CD86、CD138、CD147、HLA-DR、CEA、CSAp、CA-125、TAG-72、EFGR、HER2、HER3、HER4、IGF-1R、c-Met、PDGFR、MUC1、MUC2、MUC3、MUC4、TNFR1、TNFR2、NGFR、Fas (CD95)、DR3、DR4、DR5、DR6、VEGF、PIGF、ED-Bフィブロネクチン、テネイシン、PSMA、PSA、カルボニックアンヒドラーゼIXおよびIL-6をターゲットとする抗体からなる群から選択されるものである、請求項1に記載のヘテロ接合体。
- 前記第一の結合アームが抗CD74モノクローナル抗体である、請求項1に記載のヘテロ接合体。
- 前記第二の結合アームが抗CD20または抗CD22モノクローナル抗体である、請求項10に記載のヘテロ接合体。
- 3つ以上の抗原に結合する多重特異性ヘテロ接合体である、請求項1に記載のヘテロ接合体。
- 前記結合アームが、ヒト、ネズミ、キメラ、霊長類化、またはヒト化抗体またはフラグメントである、請求項1に記載のヘテロ接合体。
- IgG x Fab'、IgG x sFv、F(ab')2 x Fab'、Fab' x Fab'、Fab' x sFv、(sFv x sFv)2、sFv x sFv、ダイアボディー(diabody)、トリアボディー(triabody)、テトラボディー(tetrabody)およびクィンタボディーからなる群から選択される構造を有するものである、請求項1に記載のヘテロ接合体。
- 二重特異性抗体、または3つ以上の特異結合タンパク質を有する多重特異性抗体からなる、請求項1に記載のヘテロ接合体。
- 前記二重特異性抗体が、二価のFab' x Fab'構造を有するものである、請求項15に記載のヘテロ接合体。
- 前記結合アームが、ヒト化抗CD74モノクローナル抗体およびヒト化抗CD20モノクローナル抗体を含んでなる、請求項1に記載のヘテロ接合体。
- 前記結合アームが、ヒト化抗CD74モノクローナル抗体およびヒト化抗CD22モノクローナル抗体を含んでなる、請求項1に記載のヘテロ接合体。
- 前記結合アームが、抗CD20モノクローナル抗体および抗CD80モノクローナル抗体を含んでなる、請求項1に記載のヘテロ接合体。
- 前記結合アームが、抗CD20モノクローナル抗体および抗HLA-DRモノクローナル抗体または抗CD14抗体を含んでなる、請求項1に記載のヘテロ接合体。
- 前記結合アームが、抗CD2モノクローナル抗体および抗CD25モノクローナル抗体を含んでなる、請求項1に記載のヘテロ接合体。
- 前記結合アームが、抗CD8モノクローナル抗体および抗CD25モノクローナル抗体を含んでなる、請求項1に記載のヘテロ接合体。
- 前記結合アームが、抗CD2モノクローナル抗体および抗CD147モノクローナル抗体を含んでなる、請求項1に記載のヘテロ接合体。
- キレート剤、化学療法薬、酵素、ホルモン、免疫調節剤、オリゴヌクレオチド、放射性核種、ホウ素化合物、光活性剤および毒素からなる群から選択される少なくとも一つの化合物をさらに含んでなる、請求項1に記載のヘテロ接合体。
- 前記化合物が、DTPA、DOTA、TETA、NOTA、および検出可能な標識または細胞傷害剤に接合しうる適当なペプチドからなる群から選択されるキレート剤である、請求項２４に記載のヘテロ接合体。
- 前記化合物が、アントラサイクリン、タキサン、ナイトロジェンマスタード、エチレンイミン誘導体、アルキルスルホン酸塩、ニトロソ尿素、トリアゼン、葉酸類似体、ピリミジン類似体、プリン類似体、アンチセンスオリゴヌクレオチド、転写因子の拮抗物質または阻害剤、アルカロイド、抗生物質、酵素、白金配位錯体、COX-2阻害剤、アポトーシス剤、サリドマイドおよびその誘導体、置換尿素、メチルヒドラジン誘導体、副腎皮質抑制剤または拮抗薬からなる群から選択される化学療法薬である、請求項２４に記載のヘテロ接合体。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49336503P | 2003-08-08 | 2003-08-08 | |
| US60/493,365 | 2003-08-08 | ||
| PCT/US2004/025840 WO2005014618A2 (en) | 2003-08-08 | 2004-08-09 | Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007516213A JP2007516213A (ja) | 2007-06-21 |
| JP2007516213A5 true JP2007516213A5 (ja) | 2007-08-02 |
| JP4818917B2 JP4818917B2 (ja) | 2011-11-16 |
Family
ID=34135236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006523297A Expired - Fee Related JP4818917B2 (ja) | 2003-08-08 | 2004-08-09 | 腫瘍および罹患細胞のアポトーシスを誘発するための二重特異性抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20050079184A1 (ja) |
| EP (1) | EP1651663B1 (ja) |
| JP (1) | JP4818917B2 (ja) |
| AU (2) | AU2004263538B2 (ja) |
| CA (1) | CA2534898A1 (ja) |
| IL (1) | IL173477A (ja) |
| WO (1) | WO2005014618A2 (ja) |
Families Citing this family (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9206422D0 (en) * | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
| US6820011B2 (en) | 2001-04-11 | 2004-11-16 | The Regents Of The University Of Colorado | Three-dimensional structure of complement receptor type 2 and uses thereof |
| US20050271663A1 (en) * | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| CA2447851C (en) * | 2001-06-28 | 2012-08-28 | Domantis Limited | Dual-specific ligand and its use |
| US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| US7591994B2 (en) | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| AU2003244817B2 (en) * | 2002-06-28 | 2010-08-26 | Domantis Limited | Antigen-binding immunoglobulin single variable domains and dual-specific constructs |
| JP2006523090A (ja) * | 2002-12-27 | 2006-10-12 | ドマンティス リミテッド | リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体 |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| JP2007535895A (ja) * | 2003-05-01 | 2007-12-13 | イムクローン システムズ インコーポレイティド | ヒトインシュリン様成長因子−１受容体に対する完全ヒト抗体 |
| US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
| WO2005077065A2 (en) * | 2004-02-09 | 2005-08-25 | The Regents Of The University Of California | Selective high-affinity polydentate ligands and methods of making such |
| SG151294A1 (en) * | 2004-03-23 | 2009-04-30 | Biogen Idec Inc | Receptor coupling agents and therapeutic uses thereof |
| KR101201464B1 (ko) | 2004-05-05 | 2012-11-14 | 메리맥 파마슈티컬즈, 인크. | 생물학적 활성을 조정하기 위한 이특이성 결합제 |
| US8921528B2 (en) | 2004-06-01 | 2014-12-30 | Domantis Limited | Bispecific fusion antibodies with enhanced serum half-life |
| TWI433682B (zh) | 2004-06-04 | 2014-04-11 | Genentech Inc | Cd20抗體於治療多發性硬化症之用途及用於該用途之物品 |
| BRPI0519897A2 (pt) * | 2005-02-23 | 2009-08-18 | Merrimack Pharmaceuticals Inc | método para modular a atividade ou atividades biológicas de moléculas alvo em uma célula alvo, agente de ligação biespecìfico, composição, uso de um agente de ligação biespecìfico, e, kit |
| ZA200708857B (en) * | 2005-04-22 | 2009-01-28 | Genentech Inc | Method for treating dementia or alzheimer's disease with a CD30 antibody |
| EP1874821B1 (de) | 2005-04-26 | 2013-04-17 | Trion Pharma Gmbh | Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs |
| PL2100614T3 (pl) | 2005-06-17 | 2014-02-28 | Imclone Llc | Przeciwciała przeciwko PDGFR alfa do zastosowania w leczeniu guzów nowotworowych |
| MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
| US8691224B2 (en) | 2005-11-30 | 2014-04-08 | Abbvie Inc. | Anti-Aβ globulomer 5F7 antibodies |
| ES2453941T5 (es) | 2005-11-30 | 2017-05-31 | Abbvie Inc. | Anticuerpos monoclonales contra la proteína beta amiloide y usos de los mismos |
| EP2674440B1 (en) | 2005-12-16 | 2019-07-03 | IBC Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| KR101353706B1 (ko) * | 2006-02-03 | 2014-02-18 | 유니버시티 오브 워싱톤 | 전립선 암 치료용 보강제로서의 ⅰｇｆ-ⅰｒ 길항제 |
| DK2044111T3 (en) | 2006-06-21 | 2014-11-17 | Musc Found For Res Dev | OBJECTIVE TO COMPLEMENT FACTOR H FOR TREATMENT OF DISEASES |
| ME02371B (me) | 2006-09-29 | 2016-06-20 | Oncomed Pharm Inc | Sastojci i postupci za dijagnstikovanje i tretman raka |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| EP2120915B1 (en) | 2007-01-22 | 2011-09-28 | Genentech, Inc. | Polyelectrolyte precipitation and purification of antibodies |
| EP3248617A3 (en) * | 2007-02-16 | 2018-02-21 | Merrimack Pharmaceuticals, Inc. | Antibodies against erbb3 and uses thereof |
| EP2124952A2 (en) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
| JP2008292474A (ja) * | 2007-04-27 | 2008-12-04 | Nationa Hospital Organization | 成人ｔ細胞白血病発症リスク判定方法 |
| BRPI0812398A2 (pt) * | 2007-06-06 | 2019-09-24 | Domantis Ltd | domínio variável simples de imunoglobulina anti-vegf, antagonista anti-vegf, domínio variável simples de imunoglobulina resistente à protease, uso do antagonista vegf, método para a dispensação oral ou dispensação de um medicamento ao trato gi de um paciente ou ao pulmão ou tecido pulmonar ou olho de um paciente, dispositivo de dispensação pulmonar, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor, célula hospedeira, método para produzir polipeptídeo, composição farmacêutica, polipeptídeo, e, proteína de fusão |
| AU2008282729B2 (en) * | 2007-08-01 | 2015-07-16 | Scott & White Healthcare | A fold-back diabody diphtheria toxin immunotoxin and methods of use |
| MX2010004740A (es) | 2007-10-30 | 2010-05-27 | Genentech Inc | Purificacion de anticuerpos por cromatografia de intercambio cationico. |
| US9078864B2 (en) | 2008-01-08 | 2015-07-14 | Akthelia Pharmaceuticals | Agonists for antimicrobial peptide systems |
| US9441034B2 (en) | 2008-03-27 | 2016-09-13 | Zymogenetics, Inc. | Compositions and methods for inhibiting PDGFRβ and VEGF-A |
| JP5623384B2 (ja) | 2008-04-21 | 2014-11-12 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 選択的高親和性リガンドおよびこれらを作製する方法 |
| PT2848625T (pt) | 2008-08-14 | 2019-10-25 | Genentech Inc | Métodos para remover um contaminante com a utilização de cromatografia de membrana de permuta iónica de deslocação de proteína indígena. |
| EA022884B1 (ru) * | 2008-08-15 | 2016-03-31 | Мерримак Фармасьютикалз, Инк. | СПОСОБ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ С ИСПОЛЬЗОВАНИЕМ АНТИ-ErbB3 АНТИТЕЛА |
| CN103599541A (zh) | 2008-09-10 | 2014-02-26 | 弗·哈夫曼-拉罗切有限公司 | 用于防止蛋白质氧化降解的组合物和方法 |
| AR073295A1 (es) | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
| US8734795B2 (en) | 2008-10-31 | 2014-05-27 | Biogen Idec Ma Inc. | Light targeting molecules and uses thereof |
| WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
| HUE062339T2 (hu) | 2009-02-13 | 2023-10-28 | Immunomedics Inc | Sejten belül hasítható kötést tartalmazó immunkonjugátumok |
| EP2418222B1 (en) | 2009-04-10 | 2016-11-02 | Osaka University | Therapeutic agent for treating diseases in which neoplastic proliferation of plasma cells occurs |
| EP3505636A1 (en) | 2009-04-27 | 2019-07-03 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| EP2445530B1 (en) * | 2009-06-24 | 2016-09-07 | The Feinstein Institute for Medical Research | Method for treating chronic lymphocytic leukemia |
| EP2453906A4 (en) | 2009-07-02 | 2014-01-15 | Musc Found For Res Dev | METHOD FOR STIMULATING THE LIVER REGENERATION |
| ES2700450T3 (es) | 2009-10-16 | 2019-02-15 | Oncomed Pharm Inc | Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores |
| AU2010314931A1 (en) | 2009-11-05 | 2012-06-21 | Taligen Therapeutics, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis |
| JP6184695B2 (ja) * | 2009-12-04 | 2017-08-23 | ジェネンテック， インコーポレイテッド | 多重特異性抗体、抗体アナログ、組成物、及び方法 |
| US9597379B1 (en) | 2010-02-09 | 2017-03-21 | David Gordon Bermudes | Protease inhibitor combination with therapeutic proteins including antibodies |
| US8771669B1 (en) | 2010-02-09 | 2014-07-08 | David Gordon Bermudes | Immunization and/or treatment of parasites and infectious agents by live bacteria |
| US8524220B1 (en) | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
| CN105001334A (zh) | 2010-02-10 | 2015-10-28 | 伊缪诺金公司 | Cd20抗体及其用途 |
| DK2544680T3 (en) | 2010-03-11 | 2015-04-27 | Merrimack Pharmaceuticals Inc | USE OF ErbB3 INHIBITORS IN TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER |
| JP5937059B2 (ja) | 2010-03-22 | 2016-06-22 | ジェネンテック， インコーポレイテッド | タンパク質含有製剤の安定化に有用な組成物及び方法 |
| US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| JP2013525484A (ja) | 2010-05-03 | 2013-06-20 | ジェネンテック， インコーポレイテッド | タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法 |
| NZ603560A (en) | 2010-05-14 | 2014-09-26 | Univ Colorado Regents | Improved complement receptor 2 (cr2) targeting groups |
| JP2013533243A (ja) | 2010-06-22 | 2013-08-22 | ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレート | 補体成分３のＣ３ｄ断片に対する抗体 |
| SI2585045T1 (sl) | 2010-06-24 | 2019-11-29 | Hoffmann La Roche | Sestavki in postopki, ki vsebujejo alkilglikozide za stabilizacijo formulacij, ki vsebujejo beljakovine |
| CA2806855A1 (en) | 2010-08-03 | 2012-02-09 | F. Hoffmann - La Roche Ag | Chronic lymphocytic leukemia (cll) biomarkers |
| CA2808187A1 (en) | 2010-08-14 | 2012-02-23 | Abbvie Inc. | Amyloid-beta binding proteins |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| CA2817216A1 (en) | 2010-11-08 | 2012-05-18 | F. Hoffmann-La Roche Ag | Subcutaneously administered anti-il-6 receptor antibody |
| AU2012229048B2 (en) * | 2011-03-16 | 2016-01-21 | Amgen Inc | Fc variants |
| WO2012145714A2 (en) | 2011-04-22 | 2012-10-26 | Emergent Product Development Seattle, Llc | Prostate-specific membrane antigen binding proteins and related compositions and methods |
| TWI583699B (zh) | 2011-09-23 | 2017-05-21 | 安可美德藥物股份有限公司 | Ｖｅｇｆ／ｄｌｌ４結合劑類及彼等之用途 |
| US9757458B2 (en) | 2011-12-05 | 2017-09-12 | Immunomedics, Inc. | Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells |
| WO2013085893A1 (en) * | 2011-12-05 | 2013-06-13 | Immunomedics, Inc. | Therapeutic use of anti-cd22 antibodies for inducing trogocytosis |
| EP3492486A1 (en) | 2011-12-22 | 2019-06-05 | F. Hoffmann-La Roche AG | Ion exchange membrane chromatography |
| US9283272B2 (en) | 2012-03-30 | 2016-03-15 | The United States Of America As Represented By The Department Of Veterans Affairs | Targeting intracellular target-binding determinants with intracellular antibodies |
| US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
| JP2015535212A (ja) | 2012-08-17 | 2015-12-10 | ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト | 補体活性化を検出するための組成物および方法 |
| US9599620B2 (en) | 2012-10-31 | 2017-03-21 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a DLL4 antagonist |
| BR112015013444B1 (pt) | 2012-12-13 | 2022-11-01 | Immunomedics, Inc | Uso de um imunoconjugado |
| US20150329638A1 (en) * | 2012-12-28 | 2015-11-19 | Biogen Ma Inc. | Use of DR6 Antagonists to Improve Motor Neuron Disease |
| US9593339B1 (en) | 2013-02-14 | 2017-03-14 | David Gordon Bermudes | Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment |
| CA3085446C (en) * | 2013-03-13 | 2022-08-09 | Ibentrus, Inc. | Protein in which electrostatic interaction is introduced within hydrophobic interaction site and preparation method thereof |
| KR102049991B1 (ko) | 2013-03-28 | 2019-12-02 | 삼성전자주식회사 | 항 c-Met/항 Her2 이중 특이 항체 |
| KR102074421B1 (ko) | 2013-03-29 | 2020-02-10 | 삼성전자주식회사 | 항 c-Met/항 EGFR 이중 특이 항체 |
| US9879081B2 (en) | 2013-06-25 | 2018-01-30 | Samsung Electronics Co., Ltd. | Protein complex, bispecific antibody including the protein complex, and method of preparation thereof |
| US20160228589A1 (en) * | 2013-09-18 | 2016-08-11 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for imaging disorders using polyspecific agents |
| WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| KR102127408B1 (ko) | 2014-01-29 | 2020-06-29 | 삼성전자주식회사 | 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체 |
| US9975960B2 (en) | 2014-05-09 | 2018-05-22 | Samsung Electronics Co., Ltd. | Anti-HER2 antibody and anti-c-Met/anti-HER2 bispecific antibodies comprising the same |
| KR102223502B1 (ko) | 2014-05-09 | 2021-03-05 | 삼성전자주식회사 | 항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용 |
| PL3204018T3 (pl) | 2014-10-07 | 2022-01-03 | Immunomedics, Inc. | Neoadiuwantowe zastosowanie koniugatów przeciwciało-lek |
| WO2016070051A2 (en) | 2014-10-31 | 2016-05-06 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| US20170058043A1 (en) * | 2014-12-06 | 2017-03-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Bispecific antibody for cancer immunotherapy |
| SG11201705632UA (en) * | 2015-01-08 | 2017-08-30 | Kyowa Hakko Kirin Co Ltd | Bispecific antibody binding to trailr2 and psma |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| WO2016132366A1 (en) | 2015-02-18 | 2016-08-25 | Enlivex Therapeutics Ltd. | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| CN113106053A (zh) | 2015-04-21 | 2021-07-13 | 恩立夫克治疗有限责任公司 | 治疗性汇集的血液凋亡细胞制剂与其用途 |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| JP6980980B2 (ja) | 2015-06-25 | 2021-12-15 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | 抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する |
| SI3316885T1 (sl) | 2015-07-01 | 2021-09-30 | Immunomedics, Inc. | Imunokonjugati protitelo-SN-38 z linkerjem CL2A |
| EP3340995A4 (en) * | 2015-08-28 | 2019-04-03 | The Trustees Of The University Of Pennsylvania | METHODS AND COMPOSITIONS FOR CELLS EXPRESSING A CHIMERIC INTRACELLULAR SIGNALING MOLECULE |
| US11649435B2 (en) | 2015-08-28 | 2023-05-16 | The Trustees Of The University Of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
| US11352426B2 (en) | 2015-09-21 | 2022-06-07 | Aptevo Research And Development Llc | CD3 binding polypeptides |
| JP6967003B2 (ja) | 2015-09-23 | 2021-11-17 | メレオ バイオファーマ ５ インコーポレイテッド | がんの処置のための方法および組成物 |
| US11730761B2 (en) | 2016-02-18 | 2023-08-22 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| WO2017192863A1 (en) | 2016-05-04 | 2017-11-09 | L.E.A.F. Holdings Group Llc | Targeted liposomal gemcitabine compositions and methods thereof |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| EP3360898A1 (en) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
| US11198722B2 (en) | 2017-10-06 | 2021-12-14 | University Of Utah Research Foundation | Immune tolerant elastin-like peptide tetramer guided nanoparticles and methods of use |
| WO2020081910A1 (en) * | 2018-10-18 | 2020-04-23 | The Brigham And Women's Hospital, Inc. | Near infrared photoimmunotherapy |
| MX2021012032A (es) | 2019-04-01 | 2021-11-03 | Genentech Inc | Composiciones y metodos para estabilizar formulaciones que contienen proteinas. |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) * | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4444744A (en) * | 1980-03-03 | 1984-04-24 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies to cell surface antigens |
| DE3008260A1 (de) * | 1980-03-04 | 1981-09-17 | Siemens AG, 1000 Berlin und 8000 München | Verfahren zum aufzeichnen von stroemungsgrenzschichten in fluessigen medien |
| US4671958A (en) * | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US4895724A (en) * | 1985-06-07 | 1990-01-23 | Pfizer Inc. | Chitosan compositions for controlled and prolonged release of macromolecules |
| US4824659A (en) * | 1985-06-07 | 1989-04-25 | Immunomedics, Inc. | Antibody conjugates |
| US5776093A (en) * | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5525338A (en) * | 1992-08-21 | 1996-06-11 | Immunomedics, Inc. | Detection and therapy of lesions with biotin/avidin conjugates |
| US4699784A (en) * | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
| US5567610A (en) * | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| FR2604092B1 (fr) * | 1986-09-19 | 1990-04-13 | Immunotech Sa | Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo |
| US5019368A (en) * | 1989-02-23 | 1991-05-28 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
| US4932412A (en) * | 1986-12-18 | 1990-06-12 | Immunomedics, Inc. | Intraoperative and endoscopic tumor detection and therapy |
| GB8720833D0 (en) * | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| US4925648A (en) * | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5229275A (en) * | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5314695A (en) * | 1990-11-13 | 1994-05-24 | Corvas International, Inc. | Tissue factor based prothrombin time reagent |
| PT627940E (pt) * | 1992-03-05 | 2003-07-31 | Univ Texas | Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados |
| US5965132A (en) * | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| JPH08500335A (ja) * | 1992-05-06 | 1996-01-16 | イムノメディクス，インコーポレイテッド | 手術，血管内手技または内視鏡手技における腫瘍および病変の検出と治療 |
| US6096289A (en) * | 1992-05-06 | 2000-08-01 | Immunomedics, Inc. | Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy |
| US5686072A (en) * | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
| WO1994009363A1 (en) * | 1992-10-14 | 1994-04-28 | Board Of Regents, The University Of Texas System | Cancer diagnosis and therapy |
| IL109666A0 (en) * | 1993-05-17 | 1994-08-26 | Immunomedics Inc | A targeting composition containing a biotin- or avidinprotein conjugate and methods for the use thereof |
| US5827690A (en) * | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5627025A (en) * | 1994-08-12 | 1997-05-06 | The Rockefeller University | Method for the identification of compounds capable of abrogating human immunodeficiency virus (HIV) infection of dendritic cells and T-lymphocytes |
| US5783186A (en) * | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
| US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| US6183744B1 (en) * | 1997-03-24 | 2001-02-06 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| WO1999002567A2 (en) * | 1997-07-08 | 1999-01-21 | Board Of Regents, The University Of Texas System | Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells |
| US20020155604A1 (en) * | 1998-02-19 | 2002-10-24 | Jeffrey A. Ledbetter | Compositions and methods for regulating lymphocyte activation |
| WO1999059633A1 (en) * | 1998-05-20 | 1999-11-25 | Immunomedics, Inc. | Therapeutics using a bispecific anti-hla class ii invariant chain x anti-pathogen antibody |
| US6475986B1 (en) * | 1999-02-02 | 2002-11-05 | Research Development Foundation | Uses of THANK, a TNF homologue that activates apoptosis |
| DE60011612T2 (de) * | 1999-04-28 | 2005-07-07 | Board of Regents, The University of Texas System, Austin | Zusammensetzungen und Verfahren zur Krebsbehandlung durch die selektive Hemmung von VEGF |
| DE10034607A1 (de) * | 2000-07-20 | 2002-02-07 | Gundram Jung | Multispezifisches Reagenz zur selektiven Stimulierung von Zelloberflächenrezeptoren |
| WO2003068821A2 (en) * | 2002-02-14 | 2003-08-21 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
| CN102174108B (zh) | 2002-03-01 | 2016-06-29 | 免疫医疗公司 | 内在化抗-cd74抗体和使用方法 |
-
2004
- 2004-08-09 WO PCT/US2004/025840 patent/WO2005014618A2/en active Application Filing
- 2004-08-09 CA CA002534898A patent/CA2534898A1/en not_active Abandoned
- 2004-08-09 AU AU2004263538A patent/AU2004263538B2/en not_active Ceased
- 2004-08-09 US US10/913,509 patent/US20050079184A1/en not_active Abandoned
- 2004-08-09 EP EP04780644.3A patent/EP1651663B1/en not_active Expired - Lifetime
- 2004-08-09 JP JP2006523297A patent/JP4818917B2/ja not_active Expired - Fee Related
-
2006
- 2006-02-01 IL IL173477A patent/IL173477A/en not_active IP Right Cessation
-
2009
- 2009-12-02 AU AU2009243493A patent/AU2009243493B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007516213A5 (ja) | ||
| Hipp et al. | A bispecific DLL3/CD3 IgG-like T-cell engaging antibody induces antitumor responses in small cell lung cancer | |
| EP3035965B1 (en) | Bi-specific monovalent diabodies that are capable of binding cd123 and cd3, and uses therof | |
| ES2887299T3 (es) | Cadena J modificada | |
| JP5214252B2 (ja) | ヒト化ｌ２４３抗体 | |
| AU2004263538B2 (en) | Bispecific antibodies for inducing apoptosis of tumor and diseased cells | |
| Getts et al. | Have we overestimated the benefit of human (ized) antibodies? | |
| JP2016520548A5 (ja) | ||
| JP2017507936A5 (ja) | ||
| Cameron et al. | Obinutuzumab: first global approval | |
| IL301527A (en) | Methods for selective expansion of gamma delta T-cell populations and preparations thereof | |
| Zekri et al. | An IgG‐based bispecific antibody for improved dual targeting in PSMA‐positive cancer | |
| JP2015524810A5 (ja) | ||
| JP2015535691A5 (ja) | ||
| JP2009502171A5 (ja) | ||
| Liu et al. | Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer | |
| WO2006116451A3 (en) | Antibodies with immune effector activity and that internalize in endosialin-positive cells | |
| JP2014515600A5 (ja) | ||
| Chu et al. | Immunotherapy with long-lived anti-CD38× anti-CD3 bispecific antibodies stimulates potent T cell-mediated killing of human myeloma cell lines and CD38+ cells in monkeys: a potential therapy for multiple myeloma | |
| CA3174090A1 (en) | Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use | |
| JP2016509585A5 (ja) | ||
| CN110551216A (zh) | 多价抗ox40抗体及其用途 | |
| JP2021509687A (ja) | 血液悪性腫瘍の治療のための併用免疫療法及び化学療法 | |
| Wang et al. | Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells | |
| Stock et al. | Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors |